The Technical Analyst
Provention Bio Inc [PRVB]
Exchange: Nasdaq Global Select Sector: Healthcare Industry: Biotechnology
Provention Bio Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-14.25% $3.43
Last updated: 3 jul 2022 - 20:46
TimeZone: America/New_York
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 219.66 mill |
| EPS: | -1.640 |
| P/E: | 0.000 |
| Earnings Date: | Aug 03, 2022 |
| SharesOutstanding: | 64.04 mill |
| Avg Daily Volume: | 0.584 mill |
| RATING 2022-07-01 |
|---|
| B |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$4.67 (36.13%) $1.239 |
| Date: 2022-07-04 |
| True Range Average |
|---|
|
+/- $0.322 ( +/- 9.39%) Range: 3.11 - 3.75 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-05-17 | Wysenski Nancy | Buy | 33 000 | Stock Option (right to buy) |
| 2022-05-17 | Catlin Avery W | Buy | 33 000 | Stock Option (right to buy) |
| 2022-05-17 | Doherty Sean M | Buy | 33 000 | Stock Option (right to buy) |
| 2022-05-17 | Osorio Benedict | Buy | 9 000 | Stock Option (right to buy) |
| 2022-05-17 | Jenkins John Kenneth | Buy | 33 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 51.29 |
| Last 100 transactions |
| Buy: 7 760 990 | Sell: 1 468 527 |
Forecast:
16:00 - $3.43
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $3.43
Forecast 2: 16:00 - $3.43
Forecast 3: 16:00 - $3.43
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $3.43 (-14.25% ) |
| Volume | 1.104 mill |
| Avg. Vol. | 0.584 mill |
| % of Avg. Vol | 189.10 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PRVB
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since 31-12-69
| Date | Signal | @ | Closed | % | Jun 29 - 16:20 | buy | $3.91 | N/A | Active |
|---|
PRVB
Latest Press Releases
2022-06-30 16:01:00 - Press Release
Provention Bio Announces Extension Of Fda User Fee Goal Date For Teplizumab To November 17, 2022
Red bank, n.j. , june 30, 2022 /prnewswire/ -- provention bio, inc. (nasdaq: prvb) (the "company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the u.s. food and drug administration (fda) has extended its review period by three months for the biologics license application (bla) for teplizumab.
2022-06-03 07:35:00 - Press Release
Provention Bio Announces The Grant Of Inducement Awards
Red bank, n.j. , june 3, 2022 /prnewswire/ -- provention bio, inc. (nasdaq: prvb) (the "company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the company granted stock options to eight new employees to purchase an aggregate of 166,000 shares of common stock.
2022-06-03 07:00:00 - Press Release
Provention Bio Announces Update To Board Of Directors
Red bank, n.j. , june 3, 2022 /prnewswire/ -- provention bio, inc. (nasdaq: prvb), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced dr. jeffrey bluestone's decision to step down as a director on the company's board of directors to focus on his other commitments, including his role as president and chief executive officer of sonoma biotherapeutics.
2022-05-12 07:30:00 - Press Release
Provention Bio To Host A May 19, 2022 Virtual Investor Event Focused On The Potential Commercial Launch Of Teplizumab Later This Year
Red bank, n.j. , may 12, 2022 /prnewswire/ -- provention bio, inc. (nasdaq: prvb) (the "company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that it will host an investor event on thursday, may 19, 2022 focused on the potential commercial launch of teplizumab in the second half of this year.
2022-05-03 07:30:00 - Press Release
Provention Bio Announces The Grant Of Inducement Awards
Red bank, n.j. , may 3, 2022 /prnewswire/ --provention bio, inc. (nasdaq: prvb) (the "company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that the company granted stock options to four new employees to purchase an aggregate of 110,000 shares of common stock.
Latest News
2022-06-03 07:30:00 - PRNewsWire
Provention Bio to Present at the Jefferies Global Healthcare Conference
RED BANK, N.J. , June 3, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a corporate presentation at the Jefferies Global Healthcare Conference on Wednesday, June 8 th 2022 at 9:00 am EST in New York City.
2022-05-19 11:23:00 - The Motley Fool
2 High-Risk, High-Reward Stocks for Contrarian Investors
2022-05-05 12:11:08 - Seeking Alpha
Provention Bio, Inc. (PRVB) CEO Ashleigh Palmer on Q1 2022 Results - Earnings Call Transcript
Provention Bio, Inc. (NASDAQ:PRVB ) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Ashleigh Palmer – Co-Founder, President, Chief Executive Officer Francisco Leon – Co-Founder & Chief Scientific Officer Thierry Chauche – Chief Financial Officer Jason Hoitt – Chief Commercial Officer Robert Doody – Vice President, Investor Relations Conference Call Participants Gregory Renza – RBC Capital Markets Thomas Smith – SVB Leerink David Hoang – SMBC Nikko Securities America, Inc Operator Good morning. My name is Kate, and I will be your conference Operator today.
2022-05-05 09:47:27 - Zacks Investment Research
Provention Bio, Inc. (PRVB) Reports Q1 Loss, Lags Revenue Estimates
Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 22.22% and 20.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-03-28 15:32:03 - Benzinga
Provention Bio's Coxsackievirus Vaccine Candidate Elicits Durable Virus-Neutralizing Antibodies At Six Months
Provention Bio Inc (NASDAQ: PRVB) announced results from the final analysis of its first-in-human PROVENT study of PRV-101, a polyvalent inactivated coxsackievirus B (CVB) vaccine candidate. Provention is developing PRV-101 for the prevention of acute CVB infection and its.
2022-02-24 14:56:05 - Seeking Alpha
Provention Bio, Inc's. (PRVB) CEO Ashleigh Palmer on Q4 2021 Results - Earnings Call Transcript
Provention Bio, Inc's. (PRVB) CEO Ashleigh Palmer on Q4 2021 Results - Earnings Call Transcript
2022-02-24 10:50:19 - Zacks Investment Research
Provention Bio, Inc. (PRVB) Reports Q4 Loss, Tops Revenue Estimates
Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 6.82% and 1.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
2022-02-10 07:30:00 - PRNewsWire
Provention Bio to Present at the Virtual SVB Leerink 11th Annual Global Healthcare Conference
RED BANK, N.J., Feb. 10, 2022 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will participate in a fireside chat presentation at the SVB Leerink 11th Annual Global Healthcare Conference on Wednesday, February 16 th, 2022 at 10:00am EST.
2022-02-04 11:08:38 - Seeking Alpha
Provention Bio: Upgrading To A Strong-Buy, Potential Cure For Type 1 Diabetes
We like the risk-reward of Provention Bio at this point and upgrading the rating to strong-buy from a buy. We accumulated a small option-sized position last week to play. The company announced its intention to re-submit the BLA for Teplizumab targeting type 1 diabetes in at-risk individuals.
2022-01-28 12:04:23 - The Motley Fool
Why Provention Bio Stock Is Soaring Today
